TON - October 2012 Vol 5 No 9

In women with metastatic breast can­cer, less frequent dosing of zoledronic acid (ZA) may be as protective as the standard monthly infusion, according to 2 studies presented at the 2012 Annual Meeting of the American So­ciety of Clinical Oncology (ASCO). Read More ›

According to an analysis of the Eastern Cooperative Oncology Group trial ECOG-E1199 by Schneider and colleagues, the development of grade 2 to 4 peripheral neuropathy in patients with operable breast cancer who received taxanes does not appear to affect clinical outcome. Read More ›

Adverse events (AEs) related to chemotherapy for metastatic breast cancer (MBC) create a substantial economic burden that is primarily explained by increased inpatient, outpatient, and pharmacy costs, said Sara A. Hurvitz, MD, of the University of California Los Angeles, who presented an economic analysis at the 2012 Annual Meeting of the American Society of Clinical Oncology. Read More ›

A “group visit” model, led by nurse practitioners, is a feasible and highly satisfactory means of following breast cancer survivors, according to 2 oncology nurse re­searchers from the Duke Cancer Cen­ter’s program. Read More ›

The American Society of Clin­ical Oncology 2012 Breast Can­cer Symposium, held September 13-15 in San Francisco, California, offered all members of the cancer team an upfront view of new data and an opportunity for one-on-one interaction with experts in the field. The following are a few re­search items of interest to oncology nurses. Read More ›